Hunan Ouya, an established pharmaceutical company, is engaged in the development and manufacturing of pharmaceutical intermediates and APIs for the generic industry. Within a decade since inception in 2007, Hunan Ouya has emerged as a trusted partner in the generic industry across Asia, Europe and other markets.   Hunan Ouya’s portfolio is spread across more than 10 therapeutic segments and specialize in development and manufacturing of pharmaceutical intermediates for Oncology and Migraine.   Hunan Ouya obtained the Drug Manufacturing License in 2019. Our manufacturing facilities are state-of-the-art, multipurpose facilities that comply with cGMP standards and meet the requirements of our customers. We are establishing 7 new GMP workshops and 1 special reaction production line in 2020.   Research and innovation is the mainstay of Hunan Ouya’s operations. We owned 18 independent intellectual property rights, submitted more than 40 invention patent applications to the State Intellectual Property Office, and were recognized as "Hunan Little Giant Enterprise" and "Hunan High-tech Enterprise".   Hunan Ouya Pharmaceutical Co., Ltd. will adhere to the concept of "science and technology as the basis, environmental protection and health", constantly develop innovative products for our domestic and foreign customers.